Outcomes of fulvestrant therapy among japanese women with advanced breast cancer: a retrospective multicenter cohort study (JBCRG-C06; Safari)

被引：15

作者：

Kawaguchi, H. ^{[1
]}

Masuda, N. ^{[2
]}

Nakayama, T. ^{[3
]}

Aogi, K. ^{[4
]}

Anan, K. ^{[5
]}

Ito, Y. ^{[6
]}

Ohtani, S. ^{[7
]}

Sato, N. ^{[8
]}

Saji, S. ^{[9
]}

Tokunaga, E. ^{[10
]}

Nakamura, S. ^{[11
]}

Hasegawa, Y. ^{[12
]}

Hattori, M. ^{[13
]}

Fujisawa, T. ^{[14
]}

Morita, S. ^{[15
]}

Yamaguchi, M. ^{[16
]}

Yamashita, T. ^{[17
]}

Yamamoto, Y. ^{[18
]}

Ohno, S. ^{[19
]}

Toi, M. ^{[20
]}

机构：

[1] Matsuyama Red Cross Hosp, Dept Breast Surg, 1 Bunkyo Cho, Matsuyama, Ehime 7908524, Japan

[2] NHO Osaka Natl Hosp, Dept Surg, Breast Oncol, Osaka 5400006, Japan

[3] Osaka Med Ctr Canc & Cardiovasc Dis, Dept Breast & Endocrine Surg, Osaka 5370025, Japan

[4] Shikoku Canc Ctr, Dept Breast Oncol, Matsuyama, Ehime 7910280, Japan

[5] Kitakyushu Municipal Med Ctr, Dept Surg, Kitakyushu, Fukuoka 8020077, Japan

[6] Canc Inst Hosp JFCR, Breast Med Oncol Dept, Tokyo 1358550, Japan

[7] Hiroshima City Hiroshima Citizens Hosp, Dept Breast Surg, Hiroshima 7308518, Japan

[8] Niigata Canc Ctr Hosp, Dept Breast Oncol, Niigata 9518566, Japan

[9] Fukushima Med Univ, Dept Med Oncol, Fukushima 9601295, Japan

[10] Kyushu Canc Ctr, Dept Breast Oncol, Fukuoka 8111395, Japan

[11] Showa Univ, Div Breast Surg Oncol, Dept Surg, Sch Med, Tokyo 1428666, Japan

[12] Hirosaki Municipal Hosp, Dept Breast Surg, Hirosaki, Aomori 0368187, Japan

[13] Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 4648681, Japan

[14] Gunma Prefectural Canc Ctr, Dept Breast Oncol, Ohta, Gunma 3738550, Japan

[15] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto 6068507, Japan

[16] JCHO Kurume Gen Hosp, Dept Breast Surg, Kurume, Fukuoka 8300013, Japan

[17] Tokyo Metropolitan Canc & Infect Dis Ctr Komagome, Dept Breast Surg, Tokyo 1138677, Japan

[18] Kumamoto Univ, Grad Sch Med Sci, Dept Breast & Endocrine Surg, Kumamoto 1358550, Japan

[19] JFCR, Breast Oncol Ctr, Canc Inst Hosp, Tokyo 1358550, Japan

[20] Kyoto Univ, Grad Sch Med, Dept Breast Surg, Kyoto 6068507, Japan

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2017年 / 163卷 / 03期

关键词：

Advanced; Breast cancer; Endocrine therapy; Fulvestrant; Metastatic; Treatment line; ANASTROZOLE; 1; MG; POSTMENOPAUSAL WOMEN; PHASE-II; DOUBLE-BLIND; 1ST-LINE TREATMENT; EXEMESTANE; TAMOXIFEN; CONSENSUS; REGIMENS; EFFICACY;

D O I：

10.1007/s10549-017-4212-x

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

This retrospective study evaluated the effect of clinical background and treatment line on time to treatment failure (TTF) in advanced/metastatic breast cancer (AMBC) patients receiving F500 in Japan (UMIN 000015168). Patients who commenced F500 treatment were registered at 16 sites in Japan. Correlations between baseline clinicopathological factors, treatment line, and TTF were investigated by Kaplan-Meier analysis. TTF data were analyzed using univariate analysis and multivariate analysis with a Cox proportional hazards model. Data for 1072 patients were available; 1031 patients (96.2%) were evaluable for efficacy. F500 was administered as first-line treatment in 2.0%, second-line in 22.7%, third-line in 26.7%, and aefourth-line in 48.6% patients. Median TTF was 5.4 months. Multivariate analysis found that earlier F500 use (first and second vs. third vs. aefourth line; hazard ratio (HR) = 0.80, 95% confidence interval (CI) 0.74-0.86; P < 0.001), longer period from AMBC diagnosis to F500 use (ae3 vs. < 3 years; HR 0.60, 95% CI 0.51-0.70; P < 0.001), and no prior palliative chemotherapy administered for unresectable or metastatic breast cancer (no vs. yes; HR 0.69, 95% CI 0.60-0.80; P < 0.001) were associated with significantly longer TTF. Among 691 patients, where information on histologic/nuclear grade was available, a low grade was also associated with a longer TTF, but this finding was not maintained among patients with recurrent breast cancer (N = 558). Among women with recurrent breast cancer, a longer DFI between a patient's initial breast cancer diagnosis and their recurrence was associated with a longer TTF on F500 therapy. Our study showed that treatment period of F500 was longer when used in earlier-line treatment. For patients on F500, TTF was also longer for patients who had not received prior palliative chemotherapy and for those who had a longer period from their AMBC diagnosis to F500 use.

引用

页码：545 / 554

页数：10

共 22 条

[1] The sequential use of endocrine treatment for advanced breast cancer: where are we? [J].

Barrios, C. ;

Forbes, J. F. ;

Jonat, W. ;

Conte, P. ;

Gradishar, W. ;

Buzdar, A. ;

Gelmon, K. ;

Gnant, M. ;

Bonneterre, J. ;

Toi, M. ;

Hudis, C. ;

Robertson, J. F. R. .

ANNALS OF ONCOLOGY, 2012, 23 (06) :1378-1386

[2] ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) [J].

Cardoso, F. ;

Costa, A. ;

Norton, L. ;

Senkus, E. ;

Aapro, M. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Biganzoli, L. ;

Blackwell, K. L. ;

Cardoso, M. J. ;

Cufer, T. ;

El Saghir, N. ;

Fallowfield, L. ;

Fenech, D. ;

Francis, P. ;

Gelmon, K. ;

Giordano, S. H. ;

Gligorov, J. ;

Goldhirsch, A. ;

Harbeck, N. ;

Houssami, N. ;

Hudis, C. ;

Kaufman, B. ;

Krop, I. ;

Kyriakides, S. ;

Lin, U. N. ;

Mayer, M. ;

Merjaver, S. D. ;

Nordstrom, E. B. ;

Pagani, O. ;

Partridge, A. ;

Penault-Llorca, F. ;

Piccart, M. J. ;

Rugo, H. ;

Sledge, G. ;

Thomssen, C. ;

van't Veer, L. ;

Vorobiof, D. ;

Vrieling, C. ;

West, N. ;

Xu, B. ;

Winer, E. .

BREAST, 2014, 23 (05) :489-502

[3] Double-blind, Randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: Results from EFECT [J].

Chia, Stephen ;

Gradishar, William ;

Mauriac, Louis ;

Bines, Jose ;

Amant, Frederic ;

Federico, Miriam ;

Fein, Luis ;

Romieu, Gilles ;

Buzdar, Aman ;

Robertson, John F. R. ;

Brufsky, Adam ;

Possinger, Kurt ;

Rennie, Pamela ;

Sapunar, Francisco ;

Lowe, Elizabeth ;

Piccart, Martine .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1664-1670

[4] Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial [J].

Di Leo, Angelo ;

Jerusalem, Guy ;

Petruzelka, Lubos ;

Torres, Roberto ;

Bondarenko, Igor N. ;

Khasanov, Rustem ;

Verhoeven, Didier ;

Pedrini, Jose L. ;

Smirnova, Iya ;

Lichinitser, Mikhail R. ;

Pendergrass, Kelly ;

Malorni, Luca ;

Garnett, Sally ;

Rukazenkov, Yuri ;

Martin, Miguel .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2014, 106 (01)

[5] Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer [J].

Di Leo, Angelo ;

Jerusalem, Guy ;

Petruzelka, Lubos ;

Torres, Roberto ;

Bondarenko, Igor N. ;

Khasanov, Rustem ;

Verhoeven, Didier ;

Pedrini, Jose L. ;

Smirnova, Iya ;

Lichinitser, Mikhail R. ;

Pendergrass, Kelly ;

Garnett, Sally ;

Lindemann, Justin P. O. ;

Sapunar, Francisco ;

Martin, Miguel .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (30) :4594-4600

[6] Fulvestrant 500 mg Versus Anastrozole 1 mg for the First-Line Treatment of Advanced Breast Cancer: Overall Survival Analysis From the Phase II FIRST Study [J].

Ellis, Matthew J. ;

Llombart-Cussac, Antonio ;

Feltl, David ;

Dewar, John A. ;

Jasiowka, Marek ;

Hewson, Nicola ;

Rukazenkov, Yuri ;

Robertson, John F. R. .

JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (32) :3781-+

[7] Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009 [J].

Goldhirsch, A. ;

Ingle, J. N. ;

Gelber, R. D. ;

Coates, A. S. ;

Thuerlimann, B. ;

Senn, H. -J. .

ANNALS OF ONCOLOGY, 2009, 20 (08) :1319-1329

[8] Drug therapy - Treatment of breast cancer [J].

Hortobagyi, GN .

NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (14) :974-984

[9] Fulvestrant Revisited: Efficacy and Safety of the 500-mg Dose [J].

Howell, Anthony ;

Sapunar, Francisco .

CLINICAL BREAST CANCER, 2011, 11 (04) :204-210

[10] Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study [J].

Kuter, Irene ;

Gee, Julia M. W. ;

Hegg, Roberto ;

Singer, Christian F. ;

Badwe, Rajendra A. ;

Lowe, Elizabeth S. ;

Emeribe, Ugochi A. ;

Anderson, Elizabeth ;

Sapunar, Francisco ;

Finlay, Pauline ;

Nicholson, Robert I. ;

Bines, Jose ;

Harbeck, Nadia .

BREAST CANCER RESEARCH AND TREATMENT, 2012, 133 (01) :237-246

← 1 2 3 →